Neuland Laboratories growth over the years

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Compounded a year	1 yr	3 yr
Revenue	+37.0%	+19.3%
EBITDA	+77.8%	+28.3%
Net Income	+40.0%	+30.6%
EPS (adj.)	+40.0%	+30.6%
Total Assets	+34.4%	+22.9%
Total Equity	+22.9%	+23.5%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

NEULANDLAB₹19,280.00

Neuland Laboratories Ltd.

· Pharma & Health

₹ CrorePeersDIVISLAB LAURUSLABS NH NATCOPHARM LALPATHLAB SAILIFE COHANCE ASTERDMMcap ₹24,872 Cr

Annuals · FY-end closes

Compounded Growth Annuals · CAGR %	1Y CAGR	3Y CAGR
Revenue	+37.0	+19.3
EBITDA	+77.8	+28.3
Net Income	+40.0	+30.6
EPS (adj.)	+40.0	+30.6
Total Assets	+34.4	+22.9
Total Equity	+22.9	+23.5

CAGR from filed annuals — needs positive start & end values.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.